KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Non-Current Assets (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Non-Current Assets for 16 consecutive years, with $24.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Assets fell 11.79% year-over-year to $24.2 million, compared with a TTM value of $101.5 million through Sep 2025, down 13.82%, and an annual FY2024 reading of $26.6 million, down 15.71% over the prior year.
  • Non-Current Assets was $24.2 million for Q3 2025 at TherapeuticsMD, down from $25.0 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $50.9 million in Q2 2021 and bottomed at $24.2 million in Q3 2025.
  • Average Non-Current Assets over 5 years is $36.4 million, with a median of $32.8 million recorded in 2023.
  • The sharpest move saw Non-Current Assets fell 6.02% in 2021, then fell 29.79% in 2022.
  • Year by year, Non-Current Assets stood at $50.0 million in 2021, then fell by 29.79% to $35.1 million in 2022, then dropped by 10.24% to $31.5 million in 2023, then decreased by 15.71% to $26.6 million in 2024, then fell by 9.02% to $24.2 million in 2025.
  • Business Quant data shows Non-Current Assets for TXMD at $24.2 million in Q3 2025, $25.0 million in Q2 2025, and $25.7 million in Q1 2025.